A UPLC-MS/MS method for the simultaneous plasma quantification of all isomeric forms of the new anti-HCV protease inhibitors boceprevir and telaprevir

Journal of Pharmaceutical and Biomedical Analysis

Volumn 78-79, Issue , 2013, Pages 217-223

  D'Avolio, Antonio ^a   De Nicolò, Amedeo ^a   Agnesod, Danilo ^a   Simiele, Marco ^a   Mohamed Abdi, Adnan ^a   Dilly Penchala, Sujan ^b   Boglione, Lucio ^a   Cariti, Giuseppe ^a   Di Perri, Giovanni ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Boceprevir; HCV; Plasma; Telaprevir; UPLC MS MS

Indexed keywords

ACETONITRILE; BOCEPREVIR; TELAPREVIR;

ACCURACY; ARTICLE; CALIBRATION; DRUG BLOOD LEVEL; DRUG STABILITY; FOOD AND DRUG ADMINISTRATION; HEPATITIS C; HUMAN; HUMAN TISSUE; LIMIT OF DETECTION; LIMIT OF QUANTITATION; NORMAL HUMAN; PRACTICE GUIDELINE; PRECIPITATION; PRIORITY JOURNAL; QUALITY CONTROL; SIGNAL NOISE RATIO; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

CHROMATOGRAPHY, LIQUID; HEPATITIS C; HUMANS; ISOMERISM; LIMIT OF DETECTION; OLIGOPEPTIDES; PROLINE; PROTEASE INHIBITORS; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; TANDEM MASS SPECTROMETRY;

EID: 84875271297     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2013.02.025     Document Type: Article

References (40)

1. Poynard T., Yuen M.F., Ratziu V., Lai C.L. Viral hepatitis C. Lancet 2003, 362:2095-2100.
2. D'Avolio A., Ciancio A., Siccardi M., Baietto L., Simiele M., Cariti G., Calcagno A., Smedile A., Cusato J., Bonora S., Rizzetto M., Di Perri G. Ribavirin pharmacokinetics and interleukin 28B plus cytochrome P450 27B1 single-nucleotide polymorphisms as predictors of response to pegylated interferon/ribavirin treatment in patients infected with hepatitis C virus genotype 1/4. Hepatology 2011, 54:2278-2279.
3. D'Avolio A., Ciancio A., Siccardi M., Smedile A., Baietto L., Simiele M., Marucco D.A., Cariti G., Calcagno A., de Requena D.G., Sciandra M., Cusato J., Troshina G., Bonora S., Rizzetto M., Di Perri G. Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associate anemia in patients receiving standard anti-HCV treatment. Ther. Drug Monit. 2012, 34:165-170.
4. D'Avolio A., Ciancio A., Siccardi M., Smedile A., Simiele M., Cusato J., Baietto L., Marucco D.A., Cariti G., Calcagno A., Gonzalez de Requena D., Sciandra M., Troshina G., Caviglia G.P., Bonora S., Rizzetto M., Di Perri G. Negative predictive value of IL28B, SLC28A2, and CYP27B1 SNPs and low RBV plasma exposure for therapeutic response to PEG/IFN-RBV treatment. Ther. Drug Monit. 2012, 34:722-728.
5. Aguilar Marucco D., Gonzalez de Requena D., Bonora S., Tettoni C., Bonasso M., De Blasi T., D'Avolio A., Sciandra M., Siccardi M., Baietto L., Trentini L., Sinicco A., Cariti G., Di Perri G. The use of trough ribavirin concentration to predict sustained virological response and haematological toxicity in HIV/HCV-co-infected patients treated with ribavirin and pegylated interferon. J. Antimicrob. Chemother. 2008, 61:919-924.
6. Pearlman B.L. Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care. Lancet Infect. Dis. 2012, 12:717-728.
7. Kieran J., Schmitz S., O'Leary A., Walsh C., Bergin C., Norris S., Barry M. The relative efficacy of boceprevir and telaprevir in the treatment of hepatitis C virus genotype 1. Clin. Infect. Dis. 2013, 56:228-235.
8. Thompson A.J., McHutchison J.G. Will IL28B polymorphism remain relevant in the era of direct-acting antiviral agents for hepatitis C virus?. Hepatology 2012, 56:373-381.
9. Butt A.A., Kanwal F. Boceprevir and telaprevir in the management of hepatitis C virus-infected patients. Clin. Infect. Dis. 2012, 54:96-104.
10. Hezode C. Boceprevir and telaprevir for the treatment of chronic hepatitis C: safety management in clinical practice. Liver Int. 2012, 32(Suppl. 1):32-38.
11. Chen K.X., Njoroge F.G., Prongay A., Pichardo J., Madison V., Girijavallabhan V. Synthesis and biological activity of macrocyclic inhibitors of hepatitis C virus (HCV) NS3 protease. Bioorg. Med. Chem. Lett. 2005, 15:4475-4478.
12. Hezode C., Forestier N., Dusheiko G., Ferenci P., Pol S., Goeser T., Bronowicki J.P., Bourliere M., Gharakhanian S., Bengtsson L., McNair L., George S., Kieffer T., Kwong A., Kauffman R.S., Alam J., Pawlotsky J.M., Zeuzem S. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N. Engl. J. Med. 2009, 360:1839-1850.
13. Berman K., Kwo P.Y. Boceprevir, an NS3 protease inhibitor of HCV. Clin. Liver Dis. 2009, 13:429-439.
14. Garg V., Chandorkar G., Yang Y., Adda N., McNair L., Alves K., Smith F., van Heeswijk R.P. The effect of CYP3A inhibitors and inducers on the pharmacokinetics of telaprevir in healthy volunteers. Br. J. Clin. Pharmacol. 2012.
15. Ghosal A., Yuan Y., Tong W., Su A.D., Gu C., Chowdhury S.K., Kishnani N.S., Alton K.B. Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor. Drug Metab. Dispos. 2011, 39:510-521.
16. Suzuki F., Suzuki Y., Sezaki H., Akuta N., Seko Y., Kawamura Y., Hosaka T., Kobayashi M., Saito S., Arase Y., Ikeda K., Mineta R., Watahiki S., Nakayasu Y., Tsuda H., Aoki K., Yamada I., Kumada H. Exploratory study on telaprevir given every 8h at 500mg or 750mg with peginterferon-alpha-2b and ribavirin in hepatitis C patients. Hepatol Res. 2012.
17. Burger D., Back D., Buggisch P., Buti M., Craxi A., Foster G., Klinker H., Larrey D., Nikitin I., Pol S., Puoti M., Romero-Gomez M., Wedemeyer H., Zeuzem S. Clinical management of drug-drug interactions in HCV therapy: challenges and solutions. J. Hepatol. 2012.
18. Farnik H., El-Duweik J., Welsch C., Sarrazin C., Lotsch J., Zeuzem S., Geisslinger G., Schmidt H. Highly sensitive determination of HCV protease inhibitors boceprevir (SCH 503034) and telaprevir (VX 950) in human plasma by LC-MS/MS. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2009, 877:4001-4006.
19. Shen J.X., Merka E.A., Dreyer D.P., Clement R.P., Hayes R.N. Stereoselective quantitation of a serine protease inhibitor using LC-MS/MS at elevated column temperature. J. Sep. Sci. 2008, 31:242-254.
20. Wang G., Hsieh Y., Cheng K.C., Morrison R.A., Venkatraman S., Njoroge F.G., Heimark L., Korfmacher W.A. Ultra-performance liquid chromatography/tandem mass spectrometric determination of diastereomers of SCH 503034 in monkey plasma. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2007, 852:92-100.
21. Center for Drug Evaluation and Research: 202258Orig1s000 - BOCEPREVIR, 2011.
22. European Medicines Agency: EMEA/H/C/002332/- BOCEPREVIR - CHMP assessment report, 2011.
23. FDA, Guidance for Industry: Bioanalytical Method Validation, 2001 (). http://fda.gov/cder/guidance/4252fnl.pdf.
24. D'Avolio A., Baietto L., Siccardi M., Sciandra M., Simiele M., Oddone V., Bonora S., Di Perri G. An HPLC-PDA method for the simultaneous quantification of the HIV integrase inhibitor raltegravir, the new nonnucleoside reverse transcriptase inhibitor etravirine, and 11 other antiretroviral agents in the plasma of HIV-infected patients. Ther. Drug Monit. 2008, 30:662-669.
25. D'Avolio A., Sciandra M., Siccardi M., Baietto L., de Requena D.G., Bonora S., Di Perri G. A simple and sensitive assay for determining plasma tipranavir concentration in the clinical setting by new HPLC method. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2007, 848:374-378.
26. D'Avolio A., Siccardi M., Sciandra M., Baietto L., Bonora S., Trentini L., Di Perri G. HPLC-MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir, and 11 other antiretroviral agents in plasma of HIV-infected patients. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2007, 859:234-240.
27. D'Avolio A., Simiele M., Baietto L., Siccardi M., Sciandra M., Patanella S., Bonora S., Di Perri G. A validated high-performance liquid chromatography-ultraviolet method for quantification of the CCR5 inhibitor maraviroc in plasma of HIV-infected patients. Ther. Drug Monit. 2010, 32:86-92.
28. D'Avolio A., Simiele M., De Francia S., Ariaudo A., Baietto L., Cusato J., Fava C., Saglio G., Di Carlo F., Di Perri G. HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib and nilotinib in human peripheral blood mononuclear cell (PBMC). J. Pharm. Biomed. Anal. 2011, 59:109-116.
29. D'Avolio A., Simiele M., Siccardi M., Baietto L., Sciandra M., Bonora S., Di Perri G. HPLC-MS method for the quantification of nine anti-HIV drugs from dry plasma spot on glass filter and their long term stability in different conditions. J. Pharm. Biomed. Anal. 2010, 52:774-780.
30. D'Avolio A., Simiele M., Siccardi M., Baietto L., Sciandra M., Oddone V., Stefani F.R., Agati S., Cusato J., Bonora S., Di Perri G. A HPLC-MS method for the simultaneous quantification of fourteen antiretroviral agents in peripheral blood mononuclear cell of HIV infected patients optimized using medium corpuscular volume evaluation. J. Pharm. Biomed. Anal. 2010, 54:779-788.
31. De Francia S., D'Avolio A., De Martino F., Pirro E., Baietto L., Siccardi M., Simiele M., Racca S., Saglio G., Di Carlo F., Di Perri G. New HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2009, 877:1721-1726.
32. Baietto L., D'Avolio A., De Rosa F.G., Garazzino S., Michelazzo M., Ventimiglia G., Siccardi M., Simiele M., Sciandra M., Di Perri G. Development and validation of a simultaneous extraction procedure for HPLC-MS quantification of daptomycin, amikacin, gentamicin, and rifampicin in human plasma. Anal. Bioanal. Chem. 2009, 396:791-798.
33. Baietto L., D'Avolio A., De Rosa F.G., Garazzino S., Patanella S., Siccardi M., Sciandra M., Di Perri G. Simultaneous quantification of linezolid, rifampicin, levofloxacin, and moxifloxacin in human plasma using high-performance liquid chromatography with UV. Ther. Drug Monit. 2009, 31:104-109.
34. Baietto L., D'Avolio A., Marra C., Simiele M., Cusato J., Pace S., Ariaudo A., De Rosa F.G., Di Perri G. Development and validation of a new method to simultaneously quantify triazoles in plasma spotted on dry sample spot devices and analysed by HPLC-MS. J. Antimicrob. Chemother. 2012, 67:2645-2649.
35. Baietto L., D'Avolio A., Ventimiglia G., De Rosa F.G., Siccardi M., Simiele M., Sciandra M., Di Perri G. Development, validation, and routine application of a high-performance liquid chromatography method coupled with a single mass detector for quantification of itraconazole, voriconazole, and posaconazole in human plasma. Antimicrob. Agents Chemother. 2010, 54:3408-3413.
36. Taylor P.J. Matrix effects: the Achilles heel of quantitative high-performance liquid chromatography-electrospray-tandem mass spectrometry. Clin. Biochem. 2005, 38:328-334.
37. Center for Drug Evaluation and Research: 201917Orig1s000 - TELAPREVIR, 2010.
38. D'Avolio A., De Nicolo A., Simiele M., Turini S., Agnesod D., Boglione L., Cusato J., Baietto L., Cariti G., Calcagno A., Sciandra M., Di Perri G., Bonora S. Development and validation of a useful HPLC-UV method for quantification of total and phosphorylated-ribavirin in blood and erythrocytes of HCV+ patients. J. Pharm. Biomed. Anal. 2012, 66:376-380.
39. D'Avolio A., Simiele M., Calcagno A., Siccardi M., Larovere G., Agati S., Baietto L., Cusato J., Tettoni M., Sciandra M., Trentini L., Di Perri G., Bonora S. Intracellular accumulation of ritonavir combined with different protease inhibitors and correlations between concentrations in plasma and peripheral blood mononuclear cells. J. Antimicrob. Chemother. 2012.
40. Simiele M., D'Avolio A., Baietto L., Siccardi M., Sciandra M., Agati S., Cusato J., Bonora S., Di Perri G. Evaluation of the mean corpuscular volume of peripheral blood mononuclear cells of HIV patients by a coulter counter to determine intracellular drug concentrations. Antimicrob. Agents Chemother. 2011, 55:2976-2978.